Brainsway
Brainsway is the developer of Deep Transcranial Magnetic Stimulation (TMS) Therapy, a patented, noninvasive, FDA-cleared solution for treating depressive episodes in adult patients suffering from major depressive disorder who have failed to achieve s.
Launch date
Employees
Market cap
CAD175m
Enterprise valuation
CAD113m (Public information from Sep 2024)
Share price
$8.19 BWAY
Burlington Massachusetts (HQ)
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 23.1m | 22.1m | 29.7m | 27.2m | 31.8m | 39.7m | 46.2m |
% growth | 41 % | (5 %) | 34 % | (8 %) | 17 % | 25 % | 16 % |
EBITDA | (6.6m) | (4.8m) | (3.3m) | (11.1m) | (2.5m) | - | - |
% EBITDA margin | (28 %) | (22 %) | (11 %) | (41 %) | (8 %) | - | - |
Profit | (10.3m) | (5.4m) | (6.5m) | (13.3m) | (4.2m) | - | - |
% profit margin | (45 %) | (24 %) | (22 %) | (49 %) | (13 %) | - | - |
R&D budget | 7.9m | 5.8m | 6.4m | 7.7m | 6.7m | - | - |
R&D % of revenue | 34 % | 26 % | 22 % | 28 % | 21 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | N/A | $27.5m | IPO |
N/A | $45.2m | Post IPO Equity | |
Total Funding | - |
Recent News about Brainsway
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.